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Abstract Aims In 2001, the Association of Amsterdam
Community Pharmacists adopted a programme to improve
the pharmaceutical care of patients who were discharged
from hospital with five or more drug prescriptions. A
comprehensive protocol for pharmaceutical care at dis-
charge (IBOM-1) was developed. The aim of the study was
to evaluate the initial IBOM protocol and to study the
effects of the protocol on drug therapy and patient satis-
faction as well as on drug use compliance and mortality.
Method A controlled intervention study involving 37
community pharmacies and 715 of their registered patients
who were discharged from a hospital and using at least five
prescribed drugs in the years 2001–2003. The intervention
included an extensive medication review and drug coun-
selling at the patient’s home. Main outcome measure
Pharmacy intervention activities, changes in medication,
discontinuation of drugs prescribed at discharge, mortality,
time spent on the intervention activities, and medication
cost savings were all evaluated. Patient satisfaction was
measured by means of a questionnaire. Results 379 and 336
patients were enrolled in the intervention and control
groups, respectively. The mean number of drugs per patient
not dispensed, concomitantly dispensed, or of which the
quantity was changed was higher in the intervention group
than in the control group (0.70 ± 1.74 vs. 0.40 ± 1.43,
0.11 ± 0.40 vs. 0.038 ± 0.26, and 0.29 ± 1.05 vs.
0.097 ± 0.52, respectively). The mean number of drugs for
which the dose or dosage form was changed was similar in
both groups. Substitution of brand for generic or vice versa
was greater in the intervention group. Changes resulting
from a PAIS signal were similar in both groups. The mean
number of drugs per patient for which contact was required
with the physician or the Pharmacy Hospital Service Desk
was higher in the intervention group (0.35 ± 0.51 vs.
0.16 ± 0.38). About 40% of home visits resulted in the
clearing of redundant drug supplies. The IBOM-1 inter-
vention did not influence discontinuation of drugs pre-
scribed at discharge, nor did it influence mortality.
Medication costs were slightly reduced. More patients of
intervention pharmacies than of control pharmacies indi-
cated that they were (very) satisfied with the drug coun-
selling by their community pharmacist upon delivery of
their discharge medication (87% vs. 50%; v2 \ 0.001).
Conclusions Structured pharmaceutical care according to
the IBOM-1 protocol led to more changes in drug therapy.
Home visits resulted in the clearing of redundant home
drug supplies. In addition, patients were highly satisfied
with the counselling at discharge from hospital by their
community pharmacist. Patient counselling at discharge
from hospital by pharmacists, therefore, appears to be a
meaningful pharmaceutical care activity.
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Impact of findings on practice
• IBOM-1 resulted in more changes in drug therapy.
• Home visits resulted in the clearing of redundant home
drug supplies.
• Patients were satisfied with pharmaceutical care
according to IBOM-1.
Introduction
Drug-related problems (DRPs), such as contraindications,
interactions, adverse drug reactions (ADRs) and inefficacy
of treatment, result from the specific drug effects in patients,
as well as from causes such as prescription errors and non-
compliance with treatment [1, 2]. In many cases, DRPs are
the underlying cause of hospital admissions [3]. Data in the
literature suggest that 3–7% of hospitalisations are the result
of DRPs [4–6].
Beyer and De Blaey [7] have calculated that, in the
Netherlands, DRPs are causing 90.000 preventable hospi-
talisations each year. A large Australian study, furthermore,
reported a prevalence rate of 0.67 for serious ADRs and
0.97% for other drug-related hospital admissions. Around a
third of these events were considered preventable [8].
A systematic review of intervention studies showed that
38 studies aimed at a reducing DRPs caused excess mor-
bidity, hospital admissions, and/or mortality [9]. In 17
studies, interventions were initiated by the pharmacist,
while in eight studies, other primary healthcare profes-
sionals initiated the intervention. Thirteen studies con-
cerned complex interventions, including (a component of)
medication review aimed at reducing the risk of falls in the
elderly.
This analysis of the literature suggests that pharmacist-
led interventions were effective in reducing hospital
admissions. However, when the analysis was limited to
randomised, controlled trials, the benefit was lost. Pooling
the results of studies in the other categories showed no
significant effects. Royal et al. [9], therefore, concluded
that there is only weak evidence for the effectiveness of
pharmacist-initiated medication review in reducing hospi-
tal admissions.
In an intervention study aimed at identifying DRPs
during and after hospitalisation, Schnipper et al. [10]
observed that medication review by a pharmacist, patient
counselling, and follow-up by telephone were associated
with a lower rate of DRPs 30 days after discharge. In a
recent, large intervention study, Wu and colleagues [11]
concluded that telephone counselling by pharmacists of
polypharmacy patients who did not adhere to their medi-
cation schemes reduced mortality.
A hospital stay often leads to changes in the drug ther-
apy of patients with chronic diseases [12]. Most patients
are older people who are often using drugs that have been
prescribed by general practitioners (GPs) as well as by
specialist physicians. Hospital specialists may add new
drugs and cancel the use of existing drugs, while patients
may still have their cancelled drugs at home [12]. Once at
home, therefore, it is not always clear to the patient which
drugs should be used and how they should be used.
In the Netherlands, discharge prescriptions are supplied
by a community pharmacy. Usually, the discharge pre-
scription is sent directly from the hospital to the pharmacy
where the patient is registered. This implies that the
pharmacy implements all changes and informs the patient
about the drugs they should use after discharge. An
important tool in this process is the pharmacy administra-
tion and information system (PAIS), in which both patient
and medication data are electronically stored. The auto-
mated processing of prescriptions includes a relatively
extensive (but still limited) check on contraindications and
interactions [13]. Warning signals of the PAIS are, there-
fore, an important contributor to reducing the number of
possible and often preventable DRPs [3, 8, 14]. However,
using a combination of structured and patient interactive
interventions may be more effectively in preventing DRPs.
Examples include: checking if discharge medication mat-
ches concomitant medication which has not been influ-
enced by the hospital stay, interactive counselling of
patients and/or carers regarding the effects, side effects and
usage of drugs prescribed at discharge, and checking
whether any stock of cancelled and/or redundant drugs is
handed in by the patient/carer.
In 2001, the Association of Amsterdam Community
Pharmacists adopted a programme to improve the phar-
maceutical care of patients who were discharged from
hospital with five or more drug prescriptions. As an initial
step, a comprehensive protocol was developed, as shown in
Table 2. The aim of the study was to evaluate the initial
IBOM protocol and to study the effects of the protocol on
drug therapy and patient satisfaction as well as on drug use
compliance and mortality.
Method
Study design
This study is based on a controlled intervention study
involving 37 community pharmacies and 715 patients
discharged from hospital over the years 2001–2003. Con-
trol pharmacies provided usual care, shown in Table 1, at
the level of the then current version of the Dutch National
Pharmacy Standard. Intervention pharmacies provided
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extended care according to the IBOM-1 protocol, as seen in
Table 2.
Pharmacies
All pharmacies in the Amsterdam area were invited to
participate. Pharmacists could indicate whether they pre-
ferred to participate as an intervention pharmacy or a
control pharmacy.
Patients
Each pharmacy was asked to include 20 patients who were
successively discharged from hospital with at least five
prescribed drugs. Exclusion criteria were discharged to a
nursing home, inability to understand Dutch, and mental
illness. The number of patients was not based on power
calculations, but on feasibility of the intervention activities
within daily pharmacy practice.
Pharmacy data processing
Discharge prescriptions were routinely entered into the
PAIS and the electronic medication record of each patient.
Data from the medication record were either extracted in
the form of a medication profile spanning a pre-specified
period, or used to produce daily medication intake schemes
or personalised patient information letters.
Privacy
The Institutional Review Board did not consider the study
to such an extent invasive of the participants’ integrity that
review by the Board was necessary. All data were pro-
cessed in accordance with Dutch privacy regulations.
Patients had to give their written consent. Each patient was
given a randomly assigned, unique number, which was
made anonymous in the questionnaires.
Measurements
Pharmacy interventions in the discharge prescription
All drugs prescribed to the patient at discharge were com-
pared with the drugs the patients used prior to hospitalisa-
tion. The following differences were recorded on study
forms: issuing of additional drugs not listed on the discharge
prescription; cancellation of a drug; change in quantity;
change of dose; change of dosage form, substitution (brand
for generic or vice versa); change of medication as the result
Table 1 Delivery of medication at discharge in 2001–2003 (A) and usual care, according to the Dutch Pharmacy Standarda (B) [15]
A1. In the Amsterdam area, in each of its six major hospitals, the Pharmacy Service Desk (PSD) routinely sends a discharge prescription by fax
to the community pharmacy where the patient is registered.
A2. Prescriptions were in the form of a list of drugs that should be dispensed to the patient, a list of drugs prescribed in the hospital. The use of
which should be continued or in the form of an overview of all medication that the patient should use. In the latter case, it was indicated which
drugs should be dispensed. The type of prescription depended on the hospital and/or the hospital department to which the patient was admitted.
B1. Preceding the release check, prescriptions are routinely checked for drug interactions and contra-indications by the PAIS.
B2. Discharge medication is delivered at the patient’s home or is picked up by the patient or carer in the pharmacy.
B3. Drugs are routinely delivered with a drug information leaflet, but patients are also often handed supplementary personalised PAIS-generated
information letters with newly prescribed drugs.
B4. When the discharge medication is collected from the pharmacy, the patient or carer is also provided with additional oral information about
newly prescribed drugs. This includes an explanation of the drugs’ actions, their use and of possible side effects.
a First edition of 1996. The current (2nd) edition was introduced in 2006 (KNMP, The Hague)
Table 2 The IBOM-1 intervention protocol
1. Review of the medication record of the patient by the pharmacist after receipt of the discharge prescription and initial processing at level 1, as
described by the Task Force on Medicines Partnership and The National Collaborative Medicines Management Services Programme [16]. This
includes a comparison of the drugs on the discharge prescription with all medication used before the hospital admission. The review also takes
account of possible home supplies.
2. Home visit by the pharmacist within 1 week after delivery of the discharge medication.
3. All patients are given a printed or handwritten overview of their medication and a daily medication intake scheme (weekly basis).
4. A copy of the latter document is sent to their GPs.
5. All drugs must be synchronised for a similar period of time.
6. Check of home supplies.
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of a PAIS warning signal; and contact with a physician
(specialist and/or GP) or Hospital Pharmacy Service Desk.
Performance of other intervention activities
Pharmacists’ other intervention activities were also recor-
ded on study forms developed specifically for use in the
intervention pharmacies. These included: making an over-
view of the medication record (medication passport); pro-
ducing a daily medication intake scheme; sending a copy of
these documents to the patient’s GP; synchronising dis-
charge and concomitant medication on time; interviewing
the patient (at home/in the pharmacy/by telephone); and
checking home supplies of drugs.
Patient satisfaction
Patients’ satisfaction with the drug counselling by their
pharmacist was studied by means of sending a question-
naire to each patient 6–9 months after their discharge.
Patients were asked to what extent they were satisfied with
the delivery of drugs and drug counselling by their phar-
macist. Patients could reply to the questions on a five-point
Likert scale.
Discontinuation of drugs newly prescribed at discharge
Nine months after hospital discharge, the medication
record was reviewed with the aim to assess whether drugs
for treatment of a chronic disease first prescribed at dis-
charge were still being used.
Mortality
The mortality rate 9 months after discharge from the hos-
pital was determined on the basis of patient data extracted
from the PAIS.
Time spent on patient counselling and costs saved
The time spent on patient counselling, the cost of supple-
mental drugs and/or costs saved by reducing the amount of
drugs dispensed at discharge were also recorded.
Data collection and analysis
After the inclusion and counselling of 20 successive
patients, the study forms and copies of the daily medication
intake schemes and discharge prescriptions were collected.
Overviews of drugs dispensed over a period of 9 months
following discharge were provided by each pharmacy. Data
were collected and analysed in SPSS 10.0. Students’ t-test
and v2-test were used. P \ 0.05 was considered significant.
Results
Basic characteristics
The intervention and control groups included 336 and 379
patients respectively. Basic characteristics of the patients
are shown in Table 3. The male/female distribution was
similar in both groups. Only the patients in the intervention
group were slightly younger and the mean number of drugs
prescribed was higher for this group. In both the inter-
vention group, as the control group, no data were missing
with respect to the basic characteristics and the intervention
measurements. The only exception is patient satisfaction:
questionnaires were received by 112 patients in the inter-
vention group and 146 in the control group. Primary rea-
sons were: patient death (22%) and loss to follow-up.
Pharmacy interventions in the discharge prescription
Distribution of intervention measurement outcomes was
skewed strongly to the left, with only few patients (less
than 5%) that had received more than one intervention of
the same type. Data were dichotomised in patients with and
without one or more pharmacy intervention. For the fol-
lowing interventions, the proportion of patients in whom
one or more interventions was higher in patients in the
intervention group than in the control group: individual
drugs dispensed, drugs not dispensed, quantity changed of
drugs that were actually dispensed change of dose, and
contact with physician or Hospital Pharmacy Service Desk
(Table 4).
Delivery of drugs and counselling
The delivery of drugs in relation to the intervention is
shown in Table 5. Intervention pharmacists counselled the
majority of patients at home (60%). Yet, a substantial
number of patients were counselled in the pharmacy (19%)
or by telephone (14%).
Table 3 Patient characteristics
Intervention
group
Control
group
P
Number of patients 336 379
Male/female 164/172 177/202 0.317
Age, mean ± SE 69.7 ± 15.0 72.7 ± 11.2 0.004
Number of drugs prescribed per
patient, mean ± SE
7.8 ± 2.6 7.1 ± 2.3 \0.001
Patients from cardiologic,
internal, and pulmonary
departments (%)
81.6 83.7 0.545
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A small number of patients (8%) were not counselled. In
the intervention group, 133 patients (39.6%) mentioned
having a problem with their medication or raised questions
about it. In the control group, 72 patients (19%) were
counselled as part of the usual care process. Some phar-
macists in the control group also visited their patients at
home to give some form of counselling (16%) or did the
counselling when patients collected their medication in the
pharmacy (3%), shown in Table 5. In this group, 38
patients (10%) mentioned having a problem with their
medication or raised questions about it.
Evaluation of intervention activities
The pharmacists’ activities concerning the execution of the
intervention are shown in Table 6. Not all intervention
activities were fully implemented by the pharmacists. Most
patients (83%) were given a printed daily medication
intake scheme. A much smaller number (38.7%) was also
given a medication overview in the form of a ‘medication
passport’. In most cases (78%) GPs were also informed.
Supplies of redundant drugs were taken in from well over
40% of patients counselled at home. In the case of 54
patients (16%) the initial IBOM-1 protocol intervention
was followed by contacting the patient at a later stage.
Follow-up to the initial counselling was given to 66
patients (21%). In 16 (4.2%) control patients any inter-
vention activity was performed.
Patient satisfaction
The percentage of patients of intervention and control
pharmacies who were (very) satisfied about the drug
counselling in the hospital was similar (46%). More
patients of intervention pharmacies, than of control
Table 4 Pharmacy interventions on discharge prescriptions
Intervention group Control group P-value v2
Number of
patients (%)
Mean number per
patient N = 336
Number of
patients (%)
Mean number per
patient N = 379
Individual drugs not dispensed 80 (23.8) 0.70 ± 1.74 53 (14.2) 0.40 ± 1.43 0.001
Additional drugs dispensed 30 (8.9) 0.11 ± 0.40 11 (2.9) 0.038 ± 0.26 0.001
Quantity changed of drugs that were actually dispensed 42 (14.3) 0.29 ± 1.05 22 (5.9) 0.097 ± 0.52 \0.001
Change of dose 44 (13.1) 0.14 ± 0.38 29 (7.8) 0.094 ± 0.35 0.020
Change of dosage form 16 (4.8) 0.06 ± 0.28 18 (4.8) 0.051 ± 0.23 0.968
Substitution brand/generic or vice versa 95 (28.3) 0.60 ± 1.22 97 (26.0) 1.21 ± 2.52 0.497
Change of medication as the result of PAIS signal 28 (8.3) 0.60 ± 1.22 28 (7.5) 1.21 ± 2.52 0.684
Contact with physician or Hospital Pharmacy Service Desk 112 (33.3) 0.35 ± 0.51 60 (16.1) 0.16 ± 0.38 \0.001
Table 5 Delivery of drugs and
counselling
Intervention group N = 336 Control group N = 379
Number % Number %
Delivered at home, no counselling 277 73.1
Delivered at home before counselling visit 38 11.3
Delivered at home, counselling by telephone 46 13.7
Delivered at home together with counselling 163 48.5 60 15.8
Delivery and counselling in the pharmacy 62 18.5 12 3.2
Delivery in pharmacy, no counselling 27 8.0 30 7.9
Table 6 Overview of pharmacy intervention activities
Intervention group N = 336
Number %
Medication overview produced 130 38.7
Daily medication intake scheme
handed out
278 82.7
Medication synchronised 37 11.0
Taking in home supplies of drugs 86 42.8a
Any intervention activity at a later
stage
54 16.1
Follow-up counselling 66 21.4b
Copy of daily medication intake
scheme was sent to GP
261 77.7
a Percentage of patients counselled at home
b Percentage of all patients counselled
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pharmacies, indicated that they were very satisfied about
the drug counselling upon delivery of their discharge
medication by their community pharmacist. In the inter-
vention patients (n = 112), 87% were very satisfied, the
median score was ‘very satisfied’, range from neutral to
very satisfied. In the control patients (n = 146), 50% were
very satisfied, the median score was ‘satisfied’, range from
dissatisfied to very satisfied. The difference was statisti-
cally significant (v2-test, P \ 0.001).
Discontinuation of drugs newly prescribed at discharge
Over a 9-month period after discharge from hospital, a few
more patients of pharmacies in the intervention group than
the control group ceased using the drugs that were first
prescribed in hospital for the chronic disease for which
they had been treated (64% vs. 58%). The difference,
however, was not significant.
Mortality
At the end of the 9-month study period, there was no dif-
ference between the mortality of patients of intervention
pharmacies and patients of control pharmacies (22% in
each group).
Time spent on patient counselling and costs saved
The time spent on patient counselling amounted to
26.3 ± 15.7 min per patient. Costs saved by reducing the
amount of drugs delivered amounted to 19.5 ± 47.9 Euros
per patient.
Discussion
With respect to the delivery of discharge medication, the
results of the present study show that intervention by
community pharmacists according to the IBOM-1 protocol
leads to a higher rate of adjustments made to the quantity
of drugs dispensed. It also leads to a higher frequency of
contact between community pharmacists and hospitals. As
we expected, there was no difference in the number of
PAIS-generated warning signals that led to a change of
pharmacotherapy. The number of adjustments made to
prescribed doses and dosage forms were also similar.
Although hospital prescriptions, at discharge, appeared to
be technically correct, they did not take sufficiently into
account the actual need of patients. Review of the medi-
cation showed that, in the majority of cases, patients
already had sufficient stock of drugs that were not dis-
pensed, rather than there being a pharmacotherapeutic
reason for not dispensing these drugs. Thus, it appears that
application of the IBOM-1 protocol improved the quality
of the drug-dispensing procedure, which resulted in a
reduced risk of accumulated supplies of (possibly redun-
dant) drugs at the patient’s home, and, to a lesser extent, in
rationalisation of pharmacotherapy.
Evaluation of the IBOM-1 protocol
In the majority of cases, the medication prescribed at dis-
charge was delivered to homes by the control pharmacies.
This implies that most patients were only informed of the
new drugs and their usage by means of the labels on the
drug packages, the patient information leaflet and, occa-
sionally, by a personalised information letter from the
pharmacy. In only 20% of cases, an additional verbal
explanation or counselling was given. Almost 40% of the
patients of intervention pharmacies mentioned that they
had some kind of problem in using their medication, or
raised a specific question about their medication when
visited at home. This suggests that the standard procedure
for dispensing discharge medication is satisfactory. Yet,
information given to patients is not.
The most important part of the IBOM-1 intervention is
the counselling of patients at home, on the basis of an in-
depth review of their medication and a printed copy of the
daily medication intake scheme for the period of 1 week
for each patient. Indeed, 83% of patients of intervention
pharmacies were given a daily medication intake scheme.
As intended, 92% of patients were counselled, but only
60% were paid a home visit. This means that, in a con-
siderable number of cases, there was no opportunity to
check home supplies of prescription as well as non-pre-
scription drugs.
According to the study data, in only 39% of cases was a
medication overview or ‘medication passport’ produced in
the intervention pharmacies. However, with the more
important daily medication intake scheme available, the
issuing of this document, which, as its name suggests, was
initially conceived as a useful document for patients going
on holiday abroad, might be considered redundant. For this
reason, it was skipped by many pharmacies.
In view of the number of patients counselled and the
number of daily medication intake schemes handed out to
patients and sent to GPs, it can be concluded that, in the
majority of cases, the medication has been reviewed and
dispensed as intended by the IBOM-1 protocol. Around a
fifth of the patients were not given a daily medication
intake scheme. It is well possible that, in these cases, there
had been no changes in the medication after discharge and,
therefore, it was considered unnecessary to hand out a daily
medication intake scheme. In relatively few cases, medi-
cation was synchronised. This low percentage may result
from the earlier decision whether or not to dispense a drug,
Pharm World Sci (2009) 31:630–637 635
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and the possibility that synchronisation was performed
automatically on the basis of stock positions according to
the PAIS.
When patients were visited at home, in about 40 percent
of the cases, cancelled and/or redundant drugs were taken
in. On many study forms, this item was not ticked off,
which suggests that some pharmacists did not fully
implement the intervention programme. In addition, it
might not have been applicable to all patients. However, it
should be acknowledged that checking patients’ home
supplies of drugs is very important, not only because
unnecessary and redundant drugs may lead to confusion
about which drugs should be used, which can result in
various DRPs, but also because the use of any OTC drugs
can thus be determined.
Effectiveness of the IBOM-1 intervention
The effectiveness of the intervention, with respect to DRPs
and hospital admissions, has not been evaluated. However,
with respect to continuation of drugs newly prescribed in
the hospital, and mortality, the effect appears to be limited.
A similar amount of patients discontinued the use of drugs
for their chronic illness in the intervention and the control
groups. This is consistent with Herings et al. [17], who also
found low rates of persistence with chronic medication on
the basis of data from a prescription database. Also, there
was no effect on mortality.
Other studies [e.g. 18–23] have shown that home-based
interventions provide a valuable tool for detecting prob-
lems that are likely to be a cause of poor health outcomes.
The effects of these interventions on the occurrence of
hospital admissions varied, and the interventions did not
influence the number of readmissions [18, 20–23]. One of
the factors that may account for the lack of effectiveness
in our study might be the unstructured character of the
medication review by the pharmacists, who were not
trained for this specific task. In addition, a single home
visit, as investigated in our study, might be insufficient. It
has been shown that interventions using multiple home
visits resulted in positive outcomes on multiple readmis-
sions and the number of hospital days per patient [18].
However, intervention may also result in an increase of
hospital admissions [22]. Home-based interventions might
be particularly relevant for educational purposes, as
patients are often more comfortable and prepared to learn
at home [18, 19]. However, the differences in study
objectives, settings, interventions, and outcomes make a
detailed comparison difficult. With respect to a possible
effect on mortality, it can be expected that a much larger
number of participants is required to achieve sufficient
power.
Study limitations
The participating pharmacies were not randomised.
Although the basic characteristics of patients in both
groups did not differ very much, the pharmacists that
decided to participate as intervention pharmacists may
have differed in some way from the pharmacists of control
pharmacies. The basic pharmaceutical care given by an
intervention pharmacist might already have been organised
in a more structured fashion. Furthermore, it has not been
checked by an independent observer whether changes
made by pharmacists to the patients’ drug therapy led to an
improvement in the appropriateness of the drugs dispensed.
In addition, the reasons for changes in drug regimen are not
known. Also, information on patients’ re-hospitalisations
and DRPs was not recorded and cost-effectiveness was not
studied in detail. These limitations of the study design are
being addressed in the current IBOM-2 study.
Recommendations
DRPs, and specifically ADRs, form a major cause of the
hospitalisation of patients. Polypharmacy, age of patients,
and drug compliance appear determinants for hospitalisa-
tion resulting from ADRs. In this respect, interventions
should be aimed at improving pharmacotherapy by means
of effective strategies, including intensive medication
review and stimulation of drug compliance. For this pur-
pose, we have developed an intervention study, including
medication review and patient counselling at discharge
from hospital in combination, with a follow-up period of
1 year of patient counselling aimed at improving drug
safety (IBOM-2). In this study, the effects on DRPs,
patients’ re-hospitalisation and their adherence to the drug
regimen will be studied.
Conclusion
Structured pharmaceutical care according to the IBOM-1
protocol led to more changes in drug therapy. Home visits
resulted in the clearing of redundant drug supplies. In
addition, patients were highly satisfied with the counselling
at discharge from hospital by their community pharmacist.
Patient counselling at discharge from hospital by pharma-
cists, therefore, appears to be a meaningful pharmaceutical
care activity. However, intervention by pharmacists should
also be aimed at reducing DRPs and drug-related hospital
admissions, by means of effective strategies, including
structured medication review and improvement of drug
adherence. These strategies will need to be supported by
specific training of the pharmacists and by longitudinal
contact between patients and their pharmacy after
636 Pharm World Sci (2009) 31:630–637
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discharge from hospital. For a better understanding, out-
comes such as the impact of intervention on drug adher-
ence and changes in patients’ attitudes toward their
medication should be included in future studies.
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